Eligobiotics is a new generation of antimicrobials that can be programmed to target bacteria based on their genome. Eligobiotics therefore provide a new approach to explore, understand and control bacterial ecosystems both in human and animals. They can notably be used to selectively eradicate harmful pathogens from the microbiome while sparing beneficial ones.
Paris, FR
Size (employees)
13 (est)+9%
Eligo Bioscience was founded in 2014 and is headquartered in Paris, FR
Report incorrect company information

Eligo Bioscience Office Locations

Eligo Bioscience has an office in Paris
Paris, FR (HQ)
18 Rue du Dr Roux
Show all (1)
Report incorrect company information

Eligo Bioscience Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$22.2 m

Latest funding size

$18 m

Time since last funding

7 months ago


Eligo Bioscience's latest funding round in September 2017 was reported to be $18 m. In total, Eligo Bioscience has raised $22.2 m
Report incorrect company information

Eligo Bioscience News and Updates

Eligo Bioscience reels in $20 mln Series A

Paris-based Eligo Bioscience, a microbiome company developing drugs to prevent and treat bacteria-associated diseases, has secured $20 million in Series A financing. The investors included Khosla Ventures and Seventure Partners.
Report incorrect company information